PABLO DE LA
CUEVA DOBAO
Profesor asociado de Ciencias de la Salud
Hospital General Universitario de Alicante
Alicante, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital General Universitario de Alicante (45)
2024
-
Defining well-being in psoriasis: A Delphi consensus among healthcare professionals and patients
Scientific Reports, Vol. 14, Núm. 1
-
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511
-
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Dermatologic Therapy, Vol. 2024
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
-
Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 702-711
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
-
Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 654-662
2023
-
Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review
Annals of Medicine, Vol. 55, Núm. 1, pp. 1335-1345
-
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)
Actas Dermo-Sifiliograficas
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
International Journal of Dermatology
-
Moderate to Severe Psoriasis in Older Adults: Recommendations on Management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV)
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 9, pp. 802-811
-
Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883
-
Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results
Journal of Investigational Allergology and Clinical Immunology
-
[Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T479-T487
2022
-
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting
Dermatologic Therapy, Vol. 35, Núm. 8
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406
-
Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 — Management of Special Populations, Patients With Comorbid Conditions, and Risk
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 6, pp. 583-609
-
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients
Dermatologic Therapy, Vol. 35, Núm. 12
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117